Literature DB >> 2694543

Dextromethorphan and neuromodulation: old drug coughs up new activities.

F C Tortella, M Pellicano, N G Bowery.   

Abstract

Dextromethorphan is one of the most widely used non-opioid cough suppressants, representing the active ingredient in several over-the-counter antitussive formulations. It does not possess the CNS pharmacology of other opiates in humans (i.e. analgesia, respiratory depression, abuse liability or psychotomimetic properties), but since the discovery in 1981 of high affinity recognition sites in brain for dextromethorphan a unique neuropharmacological profile has emerged for this relatively innocuous drug. Anticonvulsant and neuroprotective properties have been demonstrated, and treatment with dextromethorphan has been shown to improve the cerebrovascular and functional consequences of global cerebral ischemia. Frank Tortella and colleagues review the CNS pharmacology of dextromethorphan, its possible involvement with NMDA or sigma-receptors, and the potential clinical importance of this old 'new' drug.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2694543     DOI: 10.1016/0165-6147(89)90050-3

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  25 in total

1.  Psychosis with Vicks Formula 44-D abuse.

Authors:  M Schadel; E M Sellers
Journal:  CMAJ       Date:  1992-09-15       Impact factor: 8.262

Review 2.  Pathological laughing and crying : epidemiology, pathophysiology and treatment.

Authors:  Hal S Wortzel; Timothy J Oster; C Alan Anderson; David B Arciniegas
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 3.  Combined opioid-NMDA antagonist therapies. What advantages do they offer for the control of pain syndromes?

Authors:  Z Wiesenfeld-Hallin
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

4.  The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan.

Authors:  Eun-Joo Shin; Seung-Yeol Nah; Won-Ki Kim; Kwang Ho Ko; Wang-Kee Jhoo; Yong-Kwang Lim; Joo Young Cha; Chieh-Fu Chen; Hyoung-Chun Kim
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

Review 5.  Neuropsychopharmacological understanding for therapeutic application of morphinans.

Authors:  Eun-Joo Shin; Jau-Shyong Hong; Hyoung-Chun Kim
Journal:  Arch Pharm Res       Date:  2010-10-30       Impact factor: 4.946

6.  Effects of sigma ligands on the cloned mu-, delta- and kappa-opioid receptors co-expressed with G-protein-activated K+ (GIRK) channel in Xenopus oocytes.

Authors:  T Kobayashi; K Ikeda; T Ichikawa; S Togashi; T Kumanishi
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

7.  Behavioural and electoencephalographic interactions between haloperidol and PCP/sigma ligands in the rat.

Authors:  S Sagratella; A Scotti de Carolis; A Pèzzola; P Popoli
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

8.  Discriminative stimulus effects of dextromethorphan in the rat.

Authors:  S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1994-11       Impact factor: 4.530

9.  Drug refractory epilepsy in brain damage: effect of dextromethorphan on EEG in four patients.

Authors:  B Schmitt; R Netzer; S Fanconi; P Baumann; E Boltshauser
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-03       Impact factor: 10.154

10.  Dextromethorphan inhibits osteoclast differentiation by suppressing RANKL-induced nuclear factor-κB activation.

Authors:  Karl Wu; Tzu-Hung Lin; Houng-Chi Liou; Dai-Hua Lu; Yi-Ru Chen; Wen-Mei Fu; Rong-Sen Yang
Journal:  Osteoporos Int       Date:  2013-02-12       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.